Navigation Links
GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
Date:10/29/2008

PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) (LSE: GSK) and Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).

Under the terms of the agreement, a subsidiary of GSK will commence a tender offer to acquire all of the outstanding shares of Genelabs common stock. The board of directors of Genelabs has unanimously recommended that shareholders tender their shares in the offer.

"Genelabs has demonstrated a strong track record in HCV drug discovery and identified numerous novel classes of inhibitors that target unprecedented mechanisms in the virus's life cycle," stated Zhi Hong, SVP of the Infectious Diseases Centre for Excellence in Drug Discovery (ID CEDD) at GSK. "This arrangement, combined with our other collaborations, will give GSK a broad HCV drug discovery platform addressing novel targets and innovative therapeutic approaches."

Genelabs will become part of GSK's Drug Discovery organization and its HCV programs will be consolidated into the broad therapeutic approaches already underway internally and through external collaborations. This acquisition continues GSK's strategy of pursuing the best science, internally or externally, to bring new medicines to patients and value to the GSK pipeline.

Fred Driscoll, President & CEO of Genelabs said, "This transaction provides our shareholders with certain value at a substantial premium to our stoc
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
2. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
3. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
4. GlaxoSmithKline To Post Quarterly US Grants Report
5. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
6. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
7. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
8. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
9. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
10. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
11. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company based ... Therapeutics , Inc. The new name is derived from ... in the lungs similar to branches on a tree), ... therapeutics for the treatment of respiratory diseases. , ... to mark the company's escalation into the clinical phase ...
(Date:12/13/2014)... and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... less rosy indicators in overall global economic growth, Eugene ... optics and photonics , said in a featured talk ... on 5 December at the National Chung Hsing University ... which is being integrated into future energy supplies and ...
(Date:12/13/2014)... NC (PRWEB) December 13, 2014 According ... 3 million people between now and 2030." If a ... become the seventh most populous state in the country. ... is gathering at the Future of North Carolina Forum ... Ready? Do we have the necessary infrastructure in place? ...
(Date:12/13/2014)...  Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused ... Veronica G. H. Jordan , Ph.D., and David ... bringing the total number of directors to eight, seven ... LaFrance , Chairman, President, and Chief Executive Officer of ... appointments of Veronica and David to our board of ...
Breaking Biology Technology:Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3
... Corporation (NYSE: KMB ) today announced ... Global Nonwovens, has been named to Savoy Magazine,s ... The Top 100 listing showcases a cross section ... a diverse range of industries who demonstrate leadership and ...
... engineer Robert J. Wood has been named one of ... T. Waterman Award. Wood, an Associate Professor of ... Applied Sciences (SEAS) and a Core Member of the ... the honor with Scott Aaronson of the Massachusetts Institute ...
... 2012  On the occasion of World Kidney Day, Kibow ... from an expanded clinical trial of Renadyl™ ( http://www.Renadyl.com ... quality of life (QOL) previously established in a pilot-scale ... in the product formulation are "Generally Recognized As Safe" ...
Cached Biology Technology:Kimberly-Clark's Bob Stargel Named One of Savoy Magazine's Top 100 Most Influential Blacks in Corporate America 2Kimberly-Clark's Bob Stargel Named One of Savoy Magazine's Top 100 Most Influential Blacks in Corporate America 3Engineer Robert J. Wood to receive NSF's Alan T. Waterman Award 2Interim Clinical Trial Results Confirm Safety of Renadylâ„¢, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function 2Interim Clinical Trial Results Confirm Safety of Renadylâ„¢, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function 3
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... pollen next, you have to literally think like one. , ... are more likely to stick with it rather than invest ... student at the University of Wisconsin-Milwaukee (UWM). , Flanigan ... bees as they gather pollen ?which plant species the bees ...
... five-year, $1 million grant from the National Cancer Institute, a ... improve the effectiveness of a drug that he developed ... Waldemar Debinski, M.D., Ph.D., pioneered a method to destroy cells ... The drug is currently being tested in clinical trials and ...
... research team led by scientists at the Broad Institute of ... kind of genetic "roadmap" that can connect human diseases with ... new drugs work in human cells. Called the "Connectivity Map," ... September 29 issue of Science and in separate publications in ...
Cached Biology News:Researchers find that bumblebees' flower choice matters 2Researchers find that bumblebees' flower choice matters 3Researchers find that bumblebees' flower choice matters 4Scientist works to improve treatment for brain tumors 2Genetic 'roadmap' charts links between drugs and human disease 2Genetic 'roadmap' charts links between drugs and human disease 3
... induced prior to DNA purification increasing DNA ... single-copy BACs with the high yields associated ... kits provide the linearized vector and associated ... necessary to create a 10X human BAC ...
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... EPICENTREs patented MasterAmp™ 10X PCR ... performance and allows improved sensitivity and ... templates. Using MasterAmp™ PCR Enhancer in ... of DNA melting, increases enzyme?s thermal ...
Biology Products: